{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:41:37Z","timestamp":1790700097155,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Psychiatry"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/s2215-0366(15)00366-1","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T01:26:12Z","timestamp":1442366772000},"page":"901-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study"],"prefix":"10.1016","volume":"2","author":[{"given":"Jo","family":"Kimber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S2215-0366(15)00366-1_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1360-0443.2009.02570.x","article-title":"Mortality among opiate users: opioid maintenance therapy, age and causes of death","volume":"104","author":"Clausen","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/S2215-0366(15)00366-1_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0376-8716(01)00131-4","article-title":"Mortality of opiate users in Vienna, Austria","volume":"64","author":"Risser","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/S2215-0366(15)00366-1_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.jcp.0000245561.99036.49","article-title":"One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients","volume":"26","author":"Soyka","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/S2215-0366(15)00366-1_bib6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/S2215-0366(15)00366-1_bib7","series-title":"WHO model list of essential medicines","year":"2011"},{"key":"10.1016\/S2215-0366(15)00366-1_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","article-title":"Buprenorphine","volume":"14","author":"Lewis","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/S2215-0366(15)00366-1_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","article-title":"Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine","volume":"13","author":"Kress","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1016\/S2215-0366(15)00366-1_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.112.194308","article-title":"Roles of \u03bc-opioid receptors and nociceptin\/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates","volume":"343","author":"Cremeans","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S2215-0366(15)00366-1_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/jama.285.1.39","article-title":"Deaths attributable to methadone vs buprenorphine in France","volume":"285","author":"Auriacombe","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/S2215-0366(15)00366-1_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S2215-0366(15)00366-1_bib14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","article-title":"Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention","volume":"104","author":"Burns","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recomendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/S2215-0366(15)00366-1_bib17","series-title":"Methadone and buprenorphine for the management of opioid dependence: NICE technology appraisal guidance 114","year":"2007"},{"key":"10.1016\/S2215-0366(15)00366-1_bib18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMp038126","article-title":"Office-based practice and opioid-use disorders","volume":"349","author":"Clark","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/S2215-0366(15)00366-1_bib19","first-page":"S247","article-title":"Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care","volume":"43","author":"Schackman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S2215-0366(15)00366-1_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drugalcdep.2008.07.013","article-title":"Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients","volume":"99","author":"Jones","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/S2215-0366(15)00366-1_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09595239800187551","article-title":"Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity","volume":"17","author":"Caplehorn","year":"1998","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/S2215-0366(15)00366-1_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1360-0443.2002.00179.x","article-title":"An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam","volume":"97","author":"Buster","year":"2002","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5694\/j.1326-5377.1999.tb127675.x","article-title":"Mortality associated with New South Wales methadone programs in 1994: lives lost and saved","volume":"170","author":"Caplehorn","year":"1999","journal-title":"Med J Aust"},{"key":"10.1016\/S2215-0366(15)00366-1_bib24","series-title":"International statistical classification of diseases and related health problems","year":"1993"},{"key":"10.1016\/S2215-0366(15)00366-1_bib25","series-title":"Mortality among people who use illicit drugs: A toolkit for classifying major causes of death (NDARC Technical Report no. 301)","author":"Randall","year":"2009"},{"key":"10.1016\/S2215-0366(15)00366-1_bib26","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1360-0443.2007.02025.x","article-title":"Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study","volume":"102","author":"Davoli","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/S2215-0366(15)00366-1_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/S2215-0366(15)00366-1_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jsat.2011.05.001","article-title":"Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study","volume":"41","author":"Cousins","year":"2011","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/S2215-0366(15)00366-1_bib29","doi-asserted-by":"crossref","first-page":"b2225","DOI":"10.1136\/bmj.b2225","article-title":"Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study","volume":"338","author":"McCowan","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/S2215-0366(15)00366-1_bib30","doi-asserted-by":"crossref","first-page":"c3172","DOI":"10.1136\/bmj.c3172","article-title":"Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment","volume":"341","author":"Kimber","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/S2215-0366(15)00366-1_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2010.10.021","article-title":"Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001\u20132009","volume":"115","author":"Darke","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/S2215-0366(15)00366-1_bib32","series-title":"Accidental drug-induced deaths due to opioids in Australia","author":"Roxburgh","year":"2014"},{"key":"10.1016\/S2215-0366(15)00366-1_bib33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5694\/j.1326-5377.2005.tb06549.x","article-title":"The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia","volume":"182","author":"Degenhardt","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/S2215-0366(15)00366-1_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2009.09.013","article-title":"15-year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel","volume":"107","author":"Peles","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/S2215-0366(15)00366-1_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000113722","article-title":"Mortality in opioid-maintained patients after release from an addiction clinic","volume":"14","author":"Bauer","year":"2008","journal-title":"Eur Addict Res"},{"key":"10.1016\/S2215-0366(15)00366-1_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/pubmed\/fdr055","article-title":"Promoting recovery and preventing drug-related mortality: competing risks?","volume":"33","author":"Hickman","year":"2011","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/S2215-0366(15)00366-1_bib37","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"Am J Psychiatry"}],"container-title":["The Lancet Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036615003661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2215036615003661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T10:38:32Z","timestamp":1599561512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2215036615003661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S2215036615003661"],"URL":"https:\/\/doi.org\/10.1016\/s2215-0366(15)00366-1","relation":{},"ISSN":["2215-0366"],"issn-type":[{"value":"2215-0366","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(15)00366-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S2215-0366(15)00413-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}